Cordis buys new blood clot capture technology:
This article was originally published in Clinica
Executive Summary
Cordis has acquired AngioGuard, a Minneapolis, Minnesota-based developer of embolic containment systems, for an undisclosed amount. The system is designed to prevent a possible stroke by capturing blood clots which become dislodged during interventional procedures such as carotid stenting and saphenous vein graft stenting. It is approved for coronary applications in Europe and Cordis expects to receive approval later this year for carotid applications. The Warren, New Jersey-based company hopes to combine its carotid stents, which are currently undergoing US clinical trials, with the newly-acquired technology.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.